SNDX - What's Going On With Syndax Pharmaceuticals Stock Monday? | Benzinga
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) announced topline data from the AUGMENT-101 trial of revumenib in adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).
The AUGMENT-101 trial met its primary endpoint with a complete remission (CR) or a CR with partial hematological recovery (CRh) rate of 23% (13/57) among the 57 efficacy evaluable patients in the pooled KMT2Ar acute leukemia cohort.